Here, we leveraged adoptive transfer of TTCR-C4 in refractory or relapsed AML patients to track AML-specific T cells, elucidate AML-induced T cell states, identify the mechanisms responsible for T-cell dysfunction, and inform the design of effective anti-AML therapies. The gene discussed is C4A; the disease is acute myeloid leukemia.